Eisai Inc. (United States)

Eisai is a Japanese pharmaceutical company with significant US operations in oncology, neurology, and Alzheimer’s disease. Key products include Leqembi (lecanemab), a breakthrough therapy for early Alzheimer’s disease that reduces amyloid plaques, Lenvima (lenvatinib) for thyroid, liver, and kidney cancers, and Halaven (eribulin) for breast cancer. Eisai’s neuroscience research advances understanding and treatment of dementia and epilepsy.